Saturday, July 11, 2026

Drug profile · INN

naloxone

naloxone (NALOXONE HYDROCHLORIDE (DBL)) is a opioid receptors; mu/kappa/delta antagonist. Associated with Pfizer Australia Pty Ltd.

EMA: approved TGA: approved Various (V03) V03AB15
Patents linked 0
Pipeline programs 0
News articles 2
Drug details — naloxone

Quick answer

naloxone (NALOXONE HYDROCHLORIDE (DBL)) is a opioid receptors; mu/kappa/delta antagonist. Associated with Pfizer Australia Pty Ltd.

Key facts

INN naloxone
Brand NALOXONE HYDROCHLORIDE (DBL)
Mechanism Opioid receptors; mu/kappa/delta antagonist
Therapeutic class Various (V03)
ATC code V03AB15

Mechanism of action

Opioid receptors; mu/kappa/delta antagonist

Approval history

Authority Status Date
EMA approved
TGA approved

Recent coverage

Related & competitor drugs

  1. besilesomab Various (V09)
  2. deferasirox Various (V03)
  3. ferric citrate coordination complex Various (V03)
  4. folic acid Various (V04)
  5. sevelamer carbonate Various (V03)
  6. sugammadex sodium Various (V03)

Frequently asked questions

What is naloxone?

naloxone (NALOXONE HYDROCHLORIDE (DBL)) is a opioid receptors; mu/kappa/delta antagonist. Associated with Pfizer Australia Pty Ltd.

What is the brand name for naloxone?

NALOXONE HYDROCHLORIDE (DBL) is a marketed brand name for naloxone. Check FDA Drugs@FDA for the current US label holder and prescribing information.